Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: Drug Interaction Between Ritonavir And Sitaxsentan [Phase 1]
Phase 1 trial assessing the drug interaction between ritonavir and sitaxsentan for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan [Phase 1]
Phase 1 study assessing the effect of rifampin on the pharmacokinetics of sitaxsentan has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-09-10Clinical Trial Update: (-)-Epicatechin and Pulmonary Arterial Hypertension [Phase 1]
A Phase 1 clinical trial evaluating (-)-Epicatechin for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-08-07Clinical Trial Update: Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers [Phase 1]
A Phase 1 dose-escalation study evaluating safety, maximum tolerated dose and pharmacokinetics of a single subcutaneous dose of TransCon PEG…
-
CLINICAL_TRIALS withdrawal · 2014-02-13Clinical Trial Update: Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan [Phase 4]
A Phase 4 clinical trial evaluating combined imaging modalities in pulmonary arterial hypertension using bosentan has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2014-02-04Clinical Trial Update: Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib
A clinical trial investigating biomarkers in pulmonary arterial hypertension treated with nilotinib has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-07-08Clinical Trial Update: Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
A clinical trial investigating stress echocardiography to detect pulmonary arterial hypertension in systemic sclerosis patients has been wit…
-
CLINICAL_TRIALS withdrawal · 2013-01-30Clinical Trial Update: FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) [Phase 3]
The FREEDOM DR trial evaluating oral treprostinil, with or without ERA or PDE-5 inhibitors, for pulmonary arterial hypertension has been wit…
-
CLINICAL_TRIALS withdrawal · 2012-08-06Clinical Trial Update: Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH) [Phase 2]
A Phase 2 trial evaluating metformin as add-on therapy to standard treatment for pulmonary arterial hypertension (grade II/III) has been wit…
-
CLINICAL_TRIALS withdrawal · 2012-05-14Clinical Trial Update: A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor [Phase 3]
A Phase 3 multinational trial evaluating BPS-314d-MR for pulmonary arterial hypertension has been withdrawn; no study results are reported.
-
CLINICAL_TRIALS withdrawal · 2012-03-26Clinical Trial Update: Inhaled Treprostinil for PAH: Open-label Extension [Phase 3]
A Phase 3 open-label extension trial of inhaled treprostinil for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-03-26Clinical Trial Update: Safety and Efficacy of Inhaled Treprostinil in Patients With PAH [Phase 3]
Phase 3 trial evaluating inhaled treprostinil for pulmonary arterial hypertension has been withdrawn.
-
EMA withdrawal · 2010-12-10Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury
Thelin (sitaxentan) is being withdrawn due to reports of unpredictable serious liver injury.
-
EMA withdrawal · 2010-02-19United Therapeutics Europe Ltd withdraws its marketing authorisation application for Tyvaso
United Therapeutics Europe Ltd has withdrawn its marketing authorization application for Tyvaso with the European Medicines Agency.
-
CLINICAL_TRIALS withdrawal · 2010-02-15Clinical Trial Update: Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension [Phase 2]
The Phase 2 pediatric trial evaluating inhaled iloprost for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2009-11-13Clinical Trial Update: Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 study evaluating the addition of sildenafil to bosentan therapy for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2007-08-30Clinical Trial Update: Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension [Phase 2]
Phase 2 dose-determination safety and activity study of inhaled NX1011 for pulmonary arterial hypertension has been withdrawn.